Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of mycoplasma pneumoniae pneumonia

C. M. Salvatore, C. Techasaensiri, C. Tagliabue, K. Katz, N. Leos, A. M. Gomez, G. H. McCracken, R. D. Hardy

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Mycoplasma pneumoniae is one of the causative agents of atypical community-acquired pneumonia. Tigecy-cllne belongs to a new class of glycylcycline antimicrobials that have activity against a wide range of micro-organisms, including in vitro activity against M. pneumoniae. We investigated the effect of tigecycline on microbiologic, histologic, and immunologic indices in a murine model of M. pneumoniae pneumonia. BALB/c mice were inoculated intranasally with M. pneumoniae and treated subcutaneously with tigecycline or placebo for 6 days. Outcome variables included quantitative bronchoalveolar lavage (BAL) M. pneumoniae culture, lung histopathologic score (HPS), BAL cytokine and chemoklne concentrations (tumor necrosis factor alpha [TNF-et], gamma interferon [IFN-Y], interleukin Iß [IL-lß], IL-2, IL-4, IL-5, IL-6, IL-IO, IL-12 [p40/p70], granulocyte-macrophage colony-stimulating factor, MIP-Ia, MIG, KC, MCP-I, and IP-IO). BAL M. pneu-moniae concentrations in mice treated with tigecycline (MpTige) tended to be reduced compared with mice treated with placebo (MpPl); however this did not reach statistical significance. The lung HPS was significantly lower, as well as the parenchymal-pneumonia subscore, in the MpTige mice than in the MpPl mice. MpTige mice had significantly lower BAL cytokine concentrations of IL-lß, IL-12 (p40/p70), IFN-Y, and TNF-a; of the chemokines, MIG, MIP-Ia, and IP-IO were statistically lower in MpTige mice. While tigecycline treatment demonstrated a modest microbiologic effect, it significantly improved lung histologic inflammation and reduced pulmonary cytokines and chemokines.

Original languageEnglish (US)
Pages (from-to)1546-1551
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume53
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Mycoplasma Pneumonia
Mycoplasma pneumoniae
Chemokines
Cytokines
Lung
Bronchoalveolar Lavage
Pneumonia
Interleukin-12
Therapeutics
Placebos
Interleukin-5
Granulocyte-Macrophage Colony-Stimulating Factor
tigecycline
Interleukin-1
Interleukin-4
Interferon-gamma
Interleukin-2
Interleukin-6
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of mycoplasma pneumoniae pneumonia. / Salvatore, C. M.; Techasaensiri, C.; Tagliabue, C.; Katz, K.; Leos, N.; Gomez, A. M.; McCracken, G. H.; Hardy, R. D.

In: Antimicrobial Agents and Chemotherapy, Vol. 53, No. 4, 04.2009, p. 1546-1551.

Research output: Contribution to journalArticle

Salvatore, C. M. ; Techasaensiri, C. ; Tagliabue, C. ; Katz, K. ; Leos, N. ; Gomez, A. M. ; McCracken, G. H. ; Hardy, R. D. / Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of mycoplasma pneumoniae pneumonia. In: Antimicrobial Agents and Chemotherapy. 2009 ; Vol. 53, No. 4. pp. 1546-1551.
@article{9529e70a483b4c519205852ca1eb31f5,
title = "Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of mycoplasma pneumoniae pneumonia",
abstract = "Mycoplasma pneumoniae is one of the causative agents of atypical community-acquired pneumonia. Tigecy-cllne belongs to a new class of glycylcycline antimicrobials that have activity against a wide range of micro-organisms, including in vitro activity against M. pneumoniae. We investigated the effect of tigecycline on microbiologic, histologic, and immunologic indices in a murine model of M. pneumoniae pneumonia. BALB/c mice were inoculated intranasally with M. pneumoniae and treated subcutaneously with tigecycline or placebo for 6 days. Outcome variables included quantitative bronchoalveolar lavage (BAL) M. pneumoniae culture, lung histopathologic score (HPS), BAL cytokine and chemoklne concentrations (tumor necrosis factor alpha [TNF-et], gamma interferon [IFN-Y], interleukin I{\ss} [IL-l{\ss}], IL-2, IL-4, IL-5, IL-6, IL-IO, IL-12 [p40/p70], granulocyte-macrophage colony-stimulating factor, MIP-Ia, MIG, KC, MCP-I, and IP-IO). BAL M. pneu-moniae concentrations in mice treated with tigecycline (MpTige) tended to be reduced compared with mice treated with placebo (MpPl); however this did not reach statistical significance. The lung HPS was significantly lower, as well as the parenchymal-pneumonia subscore, in the MpTige mice than in the MpPl mice. MpTige mice had significantly lower BAL cytokine concentrations of IL-l{\ss}, IL-12 (p40/p70), IFN-Y, and TNF-a; of the chemokines, MIG, MIP-Ia, and IP-IO were statistically lower in MpTige mice. While tigecycline treatment demonstrated a modest microbiologic effect, it significantly improved lung histologic inflammation and reduced pulmonary cytokines and chemokines.",
author = "Salvatore, {C. M.} and C. Techasaensiri and C. Tagliabue and K. Katz and N. Leos and Gomez, {A. M.} and McCracken, {G. H.} and Hardy, {R. D.}",
year = "2009",
month = "4",
doi = "10.1128/AAC.00979-08",
language = "English (US)",
volume = "53",
pages = "1546--1551",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of mycoplasma pneumoniae pneumonia

AU - Salvatore, C. M.

AU - Techasaensiri, C.

AU - Tagliabue, C.

AU - Katz, K.

AU - Leos, N.

AU - Gomez, A. M.

AU - McCracken, G. H.

AU - Hardy, R. D.

PY - 2009/4

Y1 - 2009/4

N2 - Mycoplasma pneumoniae is one of the causative agents of atypical community-acquired pneumonia. Tigecy-cllne belongs to a new class of glycylcycline antimicrobials that have activity against a wide range of micro-organisms, including in vitro activity against M. pneumoniae. We investigated the effect of tigecycline on microbiologic, histologic, and immunologic indices in a murine model of M. pneumoniae pneumonia. BALB/c mice were inoculated intranasally with M. pneumoniae and treated subcutaneously with tigecycline or placebo for 6 days. Outcome variables included quantitative bronchoalveolar lavage (BAL) M. pneumoniae culture, lung histopathologic score (HPS), BAL cytokine and chemoklne concentrations (tumor necrosis factor alpha [TNF-et], gamma interferon [IFN-Y], interleukin Iß [IL-lß], IL-2, IL-4, IL-5, IL-6, IL-IO, IL-12 [p40/p70], granulocyte-macrophage colony-stimulating factor, MIP-Ia, MIG, KC, MCP-I, and IP-IO). BAL M. pneu-moniae concentrations in mice treated with tigecycline (MpTige) tended to be reduced compared with mice treated with placebo (MpPl); however this did not reach statistical significance. The lung HPS was significantly lower, as well as the parenchymal-pneumonia subscore, in the MpTige mice than in the MpPl mice. MpTige mice had significantly lower BAL cytokine concentrations of IL-lß, IL-12 (p40/p70), IFN-Y, and TNF-a; of the chemokines, MIG, MIP-Ia, and IP-IO were statistically lower in MpTige mice. While tigecycline treatment demonstrated a modest microbiologic effect, it significantly improved lung histologic inflammation and reduced pulmonary cytokines and chemokines.

AB - Mycoplasma pneumoniae is one of the causative agents of atypical community-acquired pneumonia. Tigecy-cllne belongs to a new class of glycylcycline antimicrobials that have activity against a wide range of micro-organisms, including in vitro activity against M. pneumoniae. We investigated the effect of tigecycline on microbiologic, histologic, and immunologic indices in a murine model of M. pneumoniae pneumonia. BALB/c mice were inoculated intranasally with M. pneumoniae and treated subcutaneously with tigecycline or placebo for 6 days. Outcome variables included quantitative bronchoalveolar lavage (BAL) M. pneumoniae culture, lung histopathologic score (HPS), BAL cytokine and chemoklne concentrations (tumor necrosis factor alpha [TNF-et], gamma interferon [IFN-Y], interleukin Iß [IL-lß], IL-2, IL-4, IL-5, IL-6, IL-IO, IL-12 [p40/p70], granulocyte-macrophage colony-stimulating factor, MIP-Ia, MIG, KC, MCP-I, and IP-IO). BAL M. pneu-moniae concentrations in mice treated with tigecycline (MpTige) tended to be reduced compared with mice treated with placebo (MpPl); however this did not reach statistical significance. The lung HPS was significantly lower, as well as the parenchymal-pneumonia subscore, in the MpTige mice than in the MpPl mice. MpTige mice had significantly lower BAL cytokine concentrations of IL-lß, IL-12 (p40/p70), IFN-Y, and TNF-a; of the chemokines, MIG, MIP-Ia, and IP-IO were statistically lower in MpTige mice. While tigecycline treatment demonstrated a modest microbiologic effect, it significantly improved lung histologic inflammation and reduced pulmonary cytokines and chemokines.

UR - http://www.scopus.com/inward/record.url?scp=65649118628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649118628&partnerID=8YFLogxK

U2 - 10.1128/AAC.00979-08

DO - 10.1128/AAC.00979-08

M3 - Article

C2 - 19139287

AN - SCOPUS:65649118628

VL - 53

SP - 1546

EP - 1551

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -